Hisamitsu Pharmaceutical Co., Inc. provided consolidated earnings guidance for the fiscal year ending February 28, 2023. For the period, the company expected net sales of JPY 123,000 million, operating profit of JPY 11,100 million, profit attributable to owners of parent of JPY 9,700 million and basic earnings per share of JPY 121.68.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,823 JPY | -0.31% | +2.22% | -11.32% |
11/04 | Hisamitsu Pharmaceutical Attributable Profit Up 19% in Fiscal 2024 | MT |
12/01 | Hisamitsu Pharmaceutical Lifts Fiscal-Year Targets as Nine-Month Profit, Net Sales Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.32% | 1.87B | |
+31.16% | 695B | |
+26.51% | 568B | |
-4.56% | 361B | |
+19.69% | 330B | |
+3.88% | 283B | |
+16.70% | 239B | |
+8.78% | 204B | |
-7.93% | 198B | |
+9.00% | 168B |
- Stock Market
- Equities
- 4530 Stock
- News Hisamitsu Pharmaceutical Co., Inc.
- Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2023